Notably, it was found that treatment with trastuzumab, an anti-HER2 antibody traditionally prescribed for patients with HER2+ primary tumor, was shown to be effective in improving survival outcomes of patients with HER2− tumor by eliminating CK+HER2+ CTCs [126]. Here, ERBB2 is linked to neoplasm.